Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GOVXW 
GeoVax Labs Inc (GOVXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/24/2025: GOVXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -21.43% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 3.44 | 52 Weeks Range 0.01 - 0.65 | Updated Date 06/28/2025 |
52 Weeks Range 0.01 - 0.65 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -330.18% |
Management Effectiveness
Return on Assets (TTM) -915.19% | Return on Equity (TTM) -78814.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13761977 |
Shares Outstanding - | Shares Floating 13761977 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
GeoVax Labs Inc
Company Overview
History and Background
GeoVax Labs, Inc. was founded in 2001. The company focuses on developing human vaccines, utilizing a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Its initial focus was on HIV vaccines, evolving to include vaccines for other infectious diseases and cancer.
Core Business Areas
- Vaccine Development: GeoVax develops and tests vaccines based on its MVA-VLP platform, targeting infectious diseases (HIV, Zika, Lassa fever) and cancers. These vaccines are designed to stimulate both antibody and T-cell responses.
- Licensing and Partnerships: The company licenses its MVA-VLP technology and collaborates with other organizations, including government agencies (e.g., NIH) and pharmaceutical companies, to advance vaccine development.
- Research and Development: GeoVax focuses on ongoing R&D to improve its vaccine platform and expand its pipeline of vaccine candidates.
Leadership and Structure
David Dodd is the Chairman, President and CEO. The company has a Board of Directors and a management team overseeing research, clinical trials, and corporate operations.
Top Products and Market Share
Key Offerings
- HIV Vaccine Candidates: GeoVax's primary focus has been on HIV vaccine candidates. While no product has yet achieved market approval, the company continues to conduct clinical trials. Market share is currently zero as there is no approved vaccine for HIV. Competitors include Moderna (MRNA) and other companies developing preventative and therapeutic HIV vaccines.
- Zika Vaccine Candidates: GeoVax has developed Zika vaccine candidates, seeking to address the unmet need for protection against the Zika virus. Market share is currently zero as there is no approved vaccine for Zika. Competitors include Inovio Pharmaceuticals (INO) and Takeda Pharmaceutical Company Limited (TAK).
- Lassa Fever Vaccine Candidates: GeoVax develops Lassa Fever vaccine candidates. Market share is currently zero as there is no approved vaccine for Lassa Fever. Competitors include IAVI and Emergent BioSolutions (EBS).
Market Dynamics
Industry Overview
The vaccine industry is driven by global health needs, technological advancements (e.g., mRNA vaccines), and regulatory approvals. It's a competitive landscape with established players and emerging biotech firms.
Positioning
GeoVax is a smaller player focused on its MVA-VLP platform. Its competitive advantage lies in its proprietary technology, designed to elicit strong immune responses. However, its market position is challenged by larger companies with more resources and established pipelines.
Total Addressable Market (TAM)
The TAM for vaccines is estimated to be over $50 billion, depending on the year and specific disease areas. GeoVax is positioned to capture a portion of this through licensing, partnerships, and eventual commercialization of its vaccine candidates.
Upturn SWOT Analysis
Strengths
- Proprietary MVA-VLP vaccine platform
- Potential for strong immune responses
- Partnerships with government agencies and research institutions
- Experienced leadership team
Weaknesses
- Limited financial resources
- Dependence on grant funding and partnerships
- No currently approved products
- Smaller scale compared to larger pharmaceutical companies
Opportunities
- Potential for licensing agreements
- Advancements in vaccine technology
- Government funding for vaccine development
- Growing demand for vaccines against emerging infectious diseases
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRNA
- INO
- TAK
- EBS
Competitive Landscape
GeoVax faces intense competition from larger, better-funded pharmaceutical companies. Its competitive advantage hinges on the efficacy and cost-effectiveness of its MVA-VLP platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited, driven primarily by grant funding and research advancements.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and licensing agreements. Analyst estimates vary widely given the inherent uncertainty of biotech development.
Recent Initiatives: Recent initiatives include focusing on COVID-19 vaccine development, expanding its cancer vaccine program, and securing additional grant funding.
Summary
GeoVax Labs is a biotech company with a promising MVA-VLP vaccine platform, but faces significant challenges. Its success hinges on positive clinical trial results and securing funding. Competition from larger pharmaceutical companies and regulatory hurdles pose substantial risks. The company needs to achieve key milestones to prove the efficacy of its platform.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Market research reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research. Market share estimates are approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GeoVax Labs Inc
Exchange NASDAQ | Headquaters Smyrna, GA, United States | ||
IPO Launch date 2020-09-25 | Chairman, President & CEO Mr. David Alan Dodd | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.geovax.com |
Full time employees 17 | Website https://www.geovax.com | ||
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.